Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update
CYP2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19
genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor …
genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor …
Acute coronary syndromes
BA Bergmark, N Mathenge, PA Merlini… - The Lancet, 2022 - thelancet.com
Although substantial progress has been made in the diagnosis and treatment of acute
coronary syndromes, cardiovascular disease remains the leading cause of death globally …
coronary syndromes, cardiovascular disease remains the leading cause of death globally …
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study
JJ Swen, CH van der Wouden, LEN Manson… - The Lancet, 2023 - thelancet.com
Background The benefit of pharmacogenetic testing before starting drug therapy has been
well documented for several single gene–drug combinations. However, the clinical utility of …
well documented for several single gene–drug combinations. However, the clinical utility of …
[HTML][HTML] Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA
Background Comparisons between ticagrelor and clopidogrel for the secondary prevention
of stroke in CYP2C19 loss-of-function carriers have not been extensively performed …
of stroke in CYP2C19 loss-of-function carriers have not been extensively performed …
Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis
Background Whether guided selection of antiplatelet therapy in patients undergoing
percutaneous coronary intervention (PCI) is effective in improving outcomes compared with …
percutaneous coronary intervention (PCI) is effective in improving outcomes compared with …
[HTML][HTML] Antiplatelet therapy after percutaneous coronary intervention
Antiplatelet therapy is key to reducing local thrombotic complications and systemic
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …
[HTML][HTML] Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19
1 Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute
coronary syndromes in patients presenting without persistent ST-segment elevation. Eur …
coronary syndromes in patients presenting without persistent ST-segment elevation. Eur …
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials
Aims Guidelines recommend the use of potent P2Y12 inhibitors over clopidogrel for the
reduction of ischaemic events in patients with acute coronary syndrome (ACS). However …
reduction of ischaemic events in patients with acute coronary syndrome (ACS). However …
[HTML][HTML] The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease
East Asian patients have reduced anti-ischemic benefits and increased bleeding risk during
antithrombotic therapies compared with Caucasian patients. As potent P2Y 12 receptor …
antithrombotic therapies compared with Caucasian patients. As potent P2Y 12 receptor …
Bleeding avoidance strategies in percutaneous coronary intervention
For many years, bleeding has been perceived as an unavoidable consequence of strategies
aimed at reducing thrombotic complications in patients undergoing percutaneous coronary …
aimed at reducing thrombotic complications in patients undergoing percutaneous coronary …